Lilly to buy Kelonia Therapeutics in deal worth up to $7 billion
The purchase is funded by Lilly's tirzepatide business and does not change the price, supply or coverage of any GLP-1 medicine, the company said.
Eli Lilly has agreed to acquire Kelonia Therapeutics, a Boston clinical-stage company developing CAR-T cancer therapies that are assembled inside the body rather than in a laboratory, for as much as $7.00 billion in cash [1]. Under the April 20, 2026, agreement, $3.25 billion would be paid upfront, with the rest contingent on clinical, regulatory and commercial milestones [1].
Kelonia's platform, which it calls iGPS, uses engineered lentiviral particles designed to seek out T cells in the body and insert the instructions for a chimeric antigen receptor [1]. Approved CAR-T medicines work in the opposite direction: a patient's cells are collected, reprogrammed outside the body and reinfused, often after chemotherapy to make room for them. Jacob Van Naarden, Lilly's president of oncology and head of corporate business development, said the existing approach carries "significant manufacturing, safety, and access barriers" and that "only a fraction of eligible patients actually receive them" [1].
KLN-1010, the program Lilly is buying, is a one-time intravenous treatment being tested in Phase 1 for relapsed or refractory multiple myeloma. It generates anti-BCMA CAR-T cells aimed at a protein found on the surface of myeloma cells [1]. Kelonia presented early findings during the plenary session of the 2025 American Society of Hematology Annual Meeting, and the announcement describes those results as early clinical validation with promising tolerability [1]. How many patients have been treated, how they responded and how long they have been followed have not been disclosed [1].
Chief executive Kevin Friedman said Kelonia has demonstrated "deep multiple myeloma remissions with significantly reduced complexity and cost relative to ex vivo CAR T-cell approaches" [1].
At $7.00 billion, the deal carries the largest headline value among Lilly's announced 2026 transactions. An industry review of the company's buying streak lists 2025 agreements for Verve (about $1.3 billion) and SiteOne (up to $1.0 billion), a 2024 deal for Morphic (about $3.2 billion) and a 2025 deal for Scorpion (up to $2.5 billion), plus an artificial intelligence drug discovery collaboration with Insilico Medicine worth up to $2.75 billion [2]. The same review counts roughly $18 billion in total announced potential value across the wave [2].
Tirzepatide sales are paying for the push. Lilly reported $65.2 billion in 2025 revenue, of which Mounjaro and Zepbound accounted for about $36.5 billion, and has guided for $80 billion to $83 billion in 2026 [2]. The review contrasts that position with Pfizer's $43 billion purchase of Seagen, which was struck as Pfizer's revenue fell 42 percent, from $100.3 billion in 2022 to $58.5 billion in 2023 [2].
Why it matters for patients
No GLP-1 medicine is affected by this acquisition. That includes semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound) and orforglipron (Foundayo). No change to their prices, insurance coverage or supply was disclosed alongside the announcement [1][2]. The connection is financial: tirzepatide revenue is funding bets outside diabetes and obesity [2]. The Indian... no pricing or coverage change was reported. The same review notes that Foundayo was approved April 1, 2026, is priced at $149 a month for the lowest dose through LillyDirect, and is expected to be covered under Medicare Part D at $50 a month starting in July [2].
For people with multiple myeloma, an in vivo CAR-T would remove steps that limit who can be treated and how quickly. Pre-treatment chemotherapy and weeks of manufacturing would not be needed if the technique works as designed [1]. KLN-1010 is investigational, has not been approved, and its complete results have not been released [1].
What happens next
Lilly expects the transaction to close in the second half of 2026, after regulatory clearances and other standard conditions are met, with the accounting treatment settled under GAAP at that point [1]. Lilly's first-quarter 2026 results are due April 30 [2]. Medicare Part D access to Foundayo at $50 a month is expected by July [2]. No timeline has been given for later-stage trials or a regulatory filing for KLN-1010 [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.